In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to ...

Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026.

Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...

BrainSpace, a medtech focused on neurological injuries and illnesses, received 501 (k) clearance from the FDA for its brain ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Naox Technologies has become the first medtech company to receive FDA clearance for its in-ear EEG device that can negate the ...

U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...